BGT-004 / Burgeon Therap - LARVOL DELTA

Pharmacological inhibition of GPR84 attenuates acute ovarian ischemia-reperfusion injury in mice via activation of AMPK and suppression of the NLRP3 inflammasome. (PubMed, Tissue Cell) - "The Compound C mechanistic validation was performed using BGT-004, the selective GPR84 antagonist, to avoid confounding from PBI-4050's GPR40 agonist activity. These observations collectively suggest that GPR84 antagonism ameliorates OIRI through AMPK-dependent suppression of NLRP3 inflammasome activity, identifying this receptor as a candidate for further investigation in ischemia-reperfusion injury."

Journal • Preclinical • Cardiovascular • Inflammation • Reperfusion Injury • IL18 • IL1B • MPO • NLRP3 • PTPRC

A patent review of GPR84 receptor antagonists (2020-present). (PubMed, Expert Opin Ther Pat) - "Recent work and patent filings reflect continued diversification of GPR84 antagonist chemotypes, but the translational outlook remains constrained by biological uncertainty and limited clinical validation. With only a small number of candidates - such as BAY‑3178275 and BGT‑004-currently in active development, further progress will require deeper mechanistic understanding and clearer definition of disease contexts in which GPR84 modulation may offer therapeutic benefit."

Journal • Review • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Neuralgia • Oncology • Pain • Ulcerative Colitis